CPT code 80230 represents a laboratory technical assay to quantify infliximab levels in patient specimens. Therapeutic drug monitoring for biologic agents such as infliximab is important for optimizing treatment of immune‑mediated conditions, guiding dosing decisions, and identifying subtherapeutic exposure or drug clearance. Nationally, this code captures specialized laboratory activity that supports personalized medicine and value‑based care pathways.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for infliximab testing, typical settings where the service is performed, and the types of benchmarks and policy considerations commonly associated with laboratory therapeutic drug monitoring. The publication summarizes service definitions, sites of service, and the payer landscape relevant to coverage and utilization discussions. It also highlights common operational considerations for laboratories performing quantitative infliximab assays.

Data not available in the input for associated taxonomies, ICD‑10 diagnoses, specific coverage policies, and utilization benchmarks are noted where applicable in the full publication.